A phase II clinical trial presened by Padron et al in 2022 American Society of Hematology (ASH) Annual Meeting and Exposition investigated the efficacy of ruxolitinib for the treatment of chronic myelomonocytic leukemia (CMML) by objectively measuring responses and symptom improvement (Abstract 457).
